Which statement about post-marketing data collection is true?

Which statement about post-marketing data collection is true?

• A. They are optional and rarely required
• B. They are used to monitor long-term safety and effectiveness
• C. They occur before approval
• D. They replace preclinical studies

Answer: (B)

Post-marketing data collection focuses on monitoring safety and effectiveness once a product is in real-world use. After approval, trials include only a subset of patients and limited exposure time, so rare or long-term adverse effects may not appear until broader, longer use occurs. Ongoing data gathering—through adverse event reports, observational studies, and registries—helps detect safety signals, assess how well the product works in diverse populations, and guide labeling and risk management. This activity happens after approval and complements, rather than replaces, preclinical studies that establish initial safety and pharmacology. While the specifics can vary, post-marketing surveillance is a standard part of ensuring ongoing patient safety.

Post-marketing data collection focuses on monitoring safety and effectiveness once a product is in real-world use. After approval, trials include only a subset of patients and limited exposure time, so rare or long-term adverse effects may not appear until broader, longer use occurs. Ongoing data gathering—through adverse event reports, observational studies, and registries—helps detect safety signals, assess how well the product works in diverse populations, and guide labeling and risk management. This activity happens after approval and complements, rather than replaces, preclinical studies that establish initial safety and pharmacology. While the specifics can vary, post-marketing surveillance is a standard part of ensuring ongoing patient safety.